Poseida Therapeutics Inc
NASDAQ:PSTX
Poseida Therapeutics Inc
Revenue
Poseida Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Poseida Therapeutics Inc
NASDAQ:PSTX
|
Revenue
$64.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Poseida Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Poseida Therapeutics Inc
Breakdown by Segments
Poseida Therapeutics Inc
Total Revenue:
64.7m
USD
|
Collaboration Revenue:
64.7m
USD
|
See Also
What is Poseida Therapeutics Inc's Revenue?
Revenue
64.7m
USD
Based on the financial report for Dec 31, 2023, Poseida Therapeutics Inc's Revenue amounts to 64.7m USD.
What is Poseida Therapeutics Inc's Revenue growth rate?
Revenue CAGR 1Y
-50%
Over the last year, the Revenue growth was -50%.